Cover Image
市場調查報告書

巨噬細胞菌落刺激因子1受體:開發中產品分析

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 366664
出版日期 內容資訊 英文 181 Pages
訂單完成後即時交付
價格
Back to Top
巨噬細胞菌落刺激因子1受體:開發中產品分析 Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2017
出版日期: 2017年12月29日 內容資訊: 英文 181 Pages
簡介

本報告提供以巨噬細胞菌落刺激因子1受體為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

巨噬細胞菌落刺激因子1受體 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AB Science SA
  • Amgen Inc.
  • AstraZeneca Plc
  • BCI Pharma
  • Chroma Therapeutics Limited
  • CTI BioPharma Corp.
  • Deciphera Pharmaceuticals, LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Five Prime Therapeutics, Inc.
  • Ignyta, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Plexxikon Inc.
  • SignalChem Lifesciences Corp
  • Transgene SA

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1219TDB

Summary:

According to the recently published report 'Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H2 2017'; Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 36 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.

The report 'Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2, 7, 8, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology, Genito Urinary System And Sex Hormones, Respiratory and Undisclosed which include indications Solid Tumor, Ovarian Cancer, Breast Cancer, Epithelial Ovarian Cancer, Metastatic Melanoma, Bladder Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Peritoneal Cancer, Pigmented Villonodular Synovitis, Recurrent Glioblastoma Multiforme (GBM), Tenosynovial Giant Cell Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Soft Tissue Sarcoma, Acral Lentiginous Melanoma, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Inflammation, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Papillary Thyroid Cancer, Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Bone Metastasis, Brenner Tumor, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Crohn's Disease (Regional Enteritis), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Endometrial Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gliosarcoma, Hematological Tumor, Lentigo Maligna Melanoma, Liposarcoma, Lung Adenocarcinoma, Malignant Ascites, Malignant Mesothelioma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Osteolysis, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Pheochromocytoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Renal Failure, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified, Uveal Melanoma and Von Hippel-Lindau Syndrome.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
  • The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Overview
    • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • AB Science SA
    • Amgen Inc
    • Array BioPharma Inc
    • BCI Pharma
    • Bristol-Myers Squibb Co
    • CrystalGenomics Inc
    • CTI BioPharma Corp
    • Deciphera Pharmaceuticals LLC
    • Eli Lilly and Co
    • Elsalys Biotech SAS
    • F. Hoffmann-La Roche Ltd
    • GigaGen Inc
    • Hutchison MediPharma Ltd
    • Ignyta Inc
    • Nerviano Medical Sciences Srl
    • Novartis AG
    • Pfizer Inc
    • Plexxikon Inc
    • SignalChem Lifesciences Corp
    • Syndax Pharmaceuticals Inc
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Drug Profiles
    • AMG-820 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARRY-382 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • atezolizumab + emactuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLZ-945 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabiralizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCBX-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCC-3014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELB-041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emactuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emactuzumab + RG-7876 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GW-2580 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMPL-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3022855 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize CSF1R for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSB-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pacritinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride + pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-0360324 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexidartinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-5622 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-73086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-7486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRV-6527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXDX-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibitor CSF1R for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CSF-1 Receptor for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CSF-1R for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target CSF-1R for Unspecified Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SNDX-6352 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sunitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sunitinib malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Dormant Products
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Discontinued Products
  • Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 21, 2017: Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine
      • Nov 16, 2017: Pfizer Receives FDA Approval For Sutent (Sunitinib Malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
      • Nov 13, 2017: Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer 32nd Annual Meeting
      • Nov 11, 2017: Syndax Announces Presentation of Clinical Trial Data on Drug Candidate SNDX-6352 at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
      • Nov 09, 2017: Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
      • Nov 07, 2017: Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data
      • Nov 07, 2017: Syndax to Present Data On Drug Candidate SNDX-6352 at SITC 32nd Annual Scientific Meeting
      • Oct 31, 2017: Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial Giant Cell Tumor
      • Oct 19, 2017: Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight
      • Oct 11, 2017: Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer 32nd Annual Meeting
      • Sep 28, 2017: AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017
      • Sep 19, 2017: Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT in Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery
      • Sep 14, 2017: AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment
      • Sep 11, 2017: Ignyta Provides Update on Investigational Lung Cancer Drug RXDX-105 at ESMO 2017 Congress
      • Sep 07, 2017: Ignyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1)
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AB Science SA, H2 2017
  • Pipeline by Amgen Inc, H2 2017
  • Pipeline by Array BioPharma Inc, H2 2017
  • Pipeline by BCI Pharma, H2 2017
  • Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Pipeline by CrystalGenomics Inc, H2 2017
  • Pipeline by CTI BioPharma Corp, H2 2017
  • Pipeline by Deciphera Pharmaceuticals LLC, H2 2017
  • Pipeline by Eli Lilly and Co, H2 2017
  • Pipeline by Elsalys Biotech SAS, H2 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pipeline by GigaGen Inc, H2 2017
  • Pipeline by Hutchison MediPharma Ltd, H2 2017
  • Pipeline by Ignyta Inc, H2 2017
  • Pipeline by Nerviano Medical Sciences Srl, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Plexxikon Inc, H2 2017
  • Pipeline by SignalChem Lifesciences Corp, H2 2017
  • Pipeline by Syndax Pharmaceuticals Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Dormant Products, H2 2017 (Contd..3), H2 2017
  • Dormant Products, H2 2017 (Contd..4), H2 2017
  • Dormant Products, H2 2017 (Contd..5), H2 2017
  • Dormant Products, H2 2017 (Contd..6), H2 2017
  • Discontinued Products, H2 2017
  • Discontinued Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017 (Contd..2), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top